Healthcare Moves: A Monthly Summary of Hires and Layoffs
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
Apellis Lays Off 25% of Staff and Turns Focus to Commercializing New Eye Drug
The Apellis Pharmaceuticals restructuring will save up to $300 million. It comes as the biotech continues its inquiry into the cause of a rare inflammatory complication reported in a small number of patients who received its geographic atrophy drug, Syfovre.
Tips for Greater Healthcare Practice Success in 2025
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
Apellis Drug Becomes First Approved Therapy for Vision-Loss Disorder Geographic Atrophy
The FDA approved Apellis Pharmaceuticals’ Syfovre as a treatment for geographic atrophy, a retinal disorder that is a leading cause of blindness. The drug, administered as an injection into the eye, will launch in March at the price of $2,190 per vial.
Apellis Pharma eyes a shot at getting first FDA approval in rare vision disorder
Apellis Pharmaceuticals has additional clinical data that show its drug having an effect on geographic atrophy, a rare vision-loss disorder with no FDA-approved treatment. The biotech plans to include the latest results in a new drug application being readied for submission in coming months.
Apellis taps Beam’s base-editing tech to broaden autoimmune disease scope
Fresh off its first FDA approval, Apellis Pharmaceuticals is teaming up with Beam Therapeutics, a partnership that will use Beam’s base-editing technology to develop new therapies for complement system disorders. Apellis has committed to pay Beam $75 million to kick off the alliance.
With FDA approval, Apellis can challenge AstraZeneca in rare blood disorder
The FDA approved Apellis Pharmaceuticals drug pegcetacoplan (Empaveli) as a treatment for a rare blood disorder that is currently treated with medicines sold by Alexion Pharmaceuticals, a biotech being acquired by AstraZeneca. But Apellis’s drug beat Alexion drug Soliris in a head-to-head test, and the smaller company aims to steal market share from its larger rival.
Improving the Healthcare Financial Experience to Help Care Flow
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
Immunotherapy player Apellis Pharmaceuticals raises $33M
Apellis Pharmaceuticals just raised $33M to fund exploring its immunotherapy platform in three disparate indications – disease of the bone marrow, the lungs and the eye. The round, which is a private placement of its Series C preferred stock, was led by Morningside Ventures, AJU IB Investment Co. and Epidarex Ventures. The indications are: -Paroxysmal nocturnal hemoglobinuria, […]
Apellis Pharma raises $17.6M; focuses on asthma and COPD
Kentucky-based biotech Apellis Pharmaceuticals is raising a nice chunk of change – $17.6 million, according to a regulatory filing, with aims to reach $24 million in the round – but its website is woefully out of date, so what they’re doing at present is a bit of a question mark. The company’s site says it is approaching chronic […]